In a hospital, a stockout is not a logistics footnote. It is a paused procedure, a delayed diagnosis, a clinician improvising. Yet across India's fragmented medical-supply market, stockouts remain routine. The reason is structural, and it is fixable.
The structural problem: spot-buying
Most hospitals, diagnostic labs, and clinics still buy consumables like syringes, blood collection tubes, and IV infusion sets on the spot market. They order when stock runs low, at whatever price the market offers that week. This creates two compounding failures: supply that arrives reactively (often late), and prices that swing with no protection.
The result is a system optimized for nobody: suppliers can't plan production, buyers can't plan budgets, and patients absorb the risk when an item simply isn't on the shelf.
The fix: Digital Long-Term Agreements
A Long-Term Agreement (LTA) inverts the model. Instead of reacting, the buyer commits to a volume over a defined period; in exchange, the supplier forecasts demand ahead, pre-plans shipments, and locks the price. Bonn-Weiss Group's model forecasts demand 52 weeks ahead, generates a delivery calendar at signing, and vets every shipment with quality checks and CE/BIS certification before dispatch.
What volume commitment buys
Under a Digital LTA, discount scales with committed annual volume, and price is locked for the agreement term. The company's published tier model:
| Tier | Discount | Min annual volume | Price lock |
|---|---|---|---|
| Standard | 3% | 250K units | 12 months |
| Silver | 6% | 500K units | 18 months |
| Gold | 9% | 750K units | 24 months |
| Platinum | 11% | 1M units | 24 months |
| Elite | 13% | 1.5M units | 36 months |
| Premium | 15% | 2M+ units | 36 months |
Why it matters beyond price
Locked pricing protects budgets, but the larger gain is operational: when supply is pre-planned and vetted, the stockout stops being a recurring emergency. For a procurement lead, that is the difference between managing crises and managing a calendar.
India's scale and fragmentation make it one of the hardest medical-supply markets in the world, and therefore one where a predictability-first model has the most to prove, and the most to change.